NCT05256290
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
At risk: Primary completion moved at least 2 years 3 months later, primary endpoint(s) modified.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 30 versions: 29 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Nov 3, 2025 to Mar 2028 Show 9 more changesShow less
- Primary endpoint(s) modified
- Enrollment reopened
- Eligibility criteria expanded, about 29 words
- Enrollment increased: 200 → 220 participants
- Trial sites reduced: 25 → 19 locations
- Study completion pushed from Dec 2027 to Jun 2028
- Interventions modified
- Trial arms changed: 4 → 5
- Secondary endpoints: 8 to 3
- Minor Study completion date: Jun 2026 to Dec 2027v29
- Minor Study sites: 41 to 25
- Primary completion date changed from estimate of Jul 2025 to Nov 3, 2025
Notable Primary endpoints revised (2)v27 Show 5 more changesShow less
- Trial status: Recruiting to Active, Not Recruiting
- Interventions: BDTX-1535 monotherapy (Drug) to silevertinib (BDTX-1535) monotherapy (Drug)
- Secondary endpoints: 11 to 8
- Site details revised at 41 of 41 sites
- Study title expanded, about 1 word
- Minor Study sites: 42 to 41v26
Show 23 earlier versionsHide 23 earlier versions
- Minor Study sites: 38 to 42v25
- Minor Study sites: 37 to 38v24
- Minor Study sites: 31 to 37v23
- Minor Site contacts updated at 8 of 31 sitesv22
- Minor Study sites: 24 to 31v21
- Notable Primary completion date: Jun 2024 to Jul 2025
- Eligibility criteria expanded, about 55 words
- Study sites: 26 to 24
- Study completion date: Mar 2025 to Jun 2026
- Minor Study sites: 24 to 26v19
- Notable Eligibility criteria shortened, about 3 wordsv18
- Minor Study sites: 20 to 24v17
Notable Phase: Phase 1 to Phase 1/2v16 Show 8 more changesShow less
- Enrollment target: 120 to 200
- Eligibility criteria shortened, about 77 words
- Primary endpoints revised (2)
- Study sites: 19 to 20
- Interventions: BDTX-1535 in combination with temozolomide (Drug), BDTX-1535 monotherapy (Drug) to BDTX-1535 monotherapy (Drug)
- Secondary endpoints: 18 to 11
- Study arms: 3 to 4
- Study title expanded, about 2 words
- Minor Study sites: 17 to 19v14
- Minor Study sites: 15 to 17v13
Notable Primary completion date: Apr 2023 to Jun 2024v12 Show 9 more changesShow less
- Eligibility criteria shortened, about 81 words
- Primary endpoints: 1 to 2
- Enrollment target: 90 to 120
- Study completion date: Sep 2024 to Mar 2025
- Interventions: BDTX-1535 Monotherapy (Drug), BDTX-1535 Monotherapy Dose Escalation (Drug) to BDTX-1535 in combination with temozolomide (Drug), BDTX-1535 monotherapy (Drug)
- Secondary endpoints: 8 to 18
- Study description shortened, about 105 words
- Study arms: 2 to 3
- Study title expanded, about 3 words
- Minor Study sites: 11 to 15v11
- Minor Study sites: 10 to 11v10
- Minor Study sites: 8 to 10v9
- Minor Study sites: 7 to 8v8
- Minor Study sites: 6 to 7v7
- Minor Study sites: 5 to 6v6
- Minor Study sites: 4 to 5v5
- Minor Study sites: 3 to 4
- Start date changed from estimate of Mar 2022 to Mar 31, 2022
- Minor Study sites: 2 to 3v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (3)
Arms and interventions
* Advanced/metastatic NSCLC with acquired resistance EGFR mutation (eg, C797S), following a 3rd generation EGFR inhibitor in the 1st line setting (in the absence of concurrent T790M). * Advanced/metastatic NSCLC with non-classical EGFR mutation (eg, G719X) following standard-of-care therapy with an EGFR inhibitor * Recurrent GBM with confirmed EGFR alterations (including amplification, mutation, and/or variant)
Advanced/metastatic NSCLC with a non-classical driver EGFR mutation following up to 2 lines of therapy with only 1 prior EGFR targeted regimen (third-generation preferred; other approved EGFR inhibitors acceptable)
Advanced/metastatic NSCLC with the acquired resistance C797S EGFR mutation following up to 2 lines of therapy, including only 1 EGFR targeted regimen, which must be a third generation EGFR TKI (eg, osimertinib)
Treatment-naïve (first-line) advanced/metastatic NSCLC with a non-classical driver EGFR mutation (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion. Silevertinib dose for Cohort 3 is 200 mg QD.
Treatment-naïve (first-line) advanced/metastatic NSCLC with a non-classical driver EGFR mutation (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion. Silevertinib dose for Cohort 4 is 150 mg QD.
Drugs: silevertinib monotherapy
Sites
19 sites in 2 countries
United States 17, Canada 2